Answers are grounded in this paper and cite their sources.
Approximately 12-18% of couples are infertile, according to WHO for the last 20 or 30 years. The most effective approach in the infertility treatment is assisted reproductive technology (ART). Despite the active development of this area and the constant improvement of the existing protocols, the gap between the pregnancy rate and the live birth rate reaches almost 30%. One of the serious difficulties standing in the way of the achieving a better reproductive outcome is the lag of the regulatory framework from the amount for some aspect’s elaboration, for example, the gestagens use for ART in Russia. The purpose of this review is to accumulate the latest data on the luteal phase support individualization in the post-transfer period based on biomarker — serum progesterone level, to analyze possible ways to overcome insurance and expert risks when using unregulated progesterone doses and dosage regimens, to emphasize the need for continuity in luteal phase support and pregnancy after ART to ensure the increase in the main criterion of ART effectiveness — live birth.
No takes yet. Share an insight, caveat, or question.
Пестова et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: